Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal

Valentini, Caterina Giovanna; Chiusolo, Patrizia; Bianchi, Maria Luisa; Metafuni, Elisabetta; Orlando, Nicoletta; Giammarco, Sabrina; Bacigalupo, Andrea; Sica, Simona; Teofili, Luciana

doi:10.1016/j.jcyt.2020.12.001

Cited by 18 publications

(16 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We observed a longer time to neutrophil engraftment and a significantly longer time to platelet engraftment. While some studies have suggested no difference in either neutrophil or platelet engraftment between cryopreserved and fresh allografts [2][3][4][5][6][7][8][9][10], our findings are supported by others who have shown outcomes consistent with our observations. A large retrospective study conducted by Hsu et al analyzed outcomes from 1051 frozen PBSC allografts derived from related donors and another 678 allografts derived from matched-unrelated donors [5].…”

Section: Discussionsupporting

confidence: 91%

“…Although there is plenty of evidence on the safety and efficacy of cryopreserved autograft [5], data on the outcomes of cryopreserved allo-HSCT has been mixed and limited [2][3][4][5][6][7][8][9][10][11][12][13][14]. Some studies showed increased risk of graft failure and higher mortality rate, while others showed no impact on survival or engraftment.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 pandemic: a single center experience

et al. 2022

View full text Add to dashboard Cite

Background/objective Cryopreservation of grafts is not common practice in allogeneic hematopoietic stem cell transplant (HSCT) recipients. However, our center had to use cryopreserved cells for allogeneic HSCT during the COVID-19 pandemic to avoid delays in transplantation due to uncertainty regarding patient and donor exposures. Study designWe retrospectively evaluated post-transplant engraftment and survival outcomes of adult patients who received cryopreserved versus fresh allografts during the COVID-19 pandemic. Results Fifty-five patients with hematologic malignancies received either cryopreserved (n = 34) or fresh (n = 21) allogeneic HSCT using peripheral blood stem cells between January 2020 and December 2020. At a median follow-up time of 15 months, cryopreserved allograft recipients had significantly lower overall survival (OS) (p = 0.02). They also experienced significantly delayed neutrophil (p = 0.01) and platelet engraftments (p < 0.0001), as well as higher red blood cell transfusiondependence after day + 60 (67.6% vs. 28.6%; p = 0.01). Significantly more cryopreserved allograft recipients received donor lymphocyte infusion than fresh allograft recipients (35.3% vs. 4.8%, p = 0.01). Neither relapse-free survival nor non-relapse mortality differed significantly between the two groups. Conclusion Cryopreservation of allografts in combination with post-transplant cyclophosphamide may negatively affect engraftment and OS outcomes in HSCT recipients.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 pandemic: a single center experience

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The rationale against cryopreservation was to avoid a loss in cell viability as a result of processing and storage of donor product. In a recent study, Teofili et al reported that cryopreservation, which was introduced for all related and unrelated apheresis products during the Covid 19 pandemic, did not affect transplant outcomes, including engraftment, acute GVHD, and non-relapse mortality [11] …”

Section: Discussionmentioning

confidence: 99%

Impact of Covid 19 pandemic on hematopoietic stem cell transplantation activities: Report from a single center

Giammarco¹,

Sica²,

Metafuni³

et al. 2023

Transfusion and Apheresis Science

Self Cite

View full text Add to dashboard Cite

“…Small clinical trials focused on HSCT recipients were also negatively impacted due to the pandemic. 48 , 49 Future studies analyzing the long-term effect of the pandemic on clinical research, clinical trial enrollment, and patient outcomes are needed.…”

Section: Section 2: the Impact On Research And Cancer-related Therapy...mentioning

confidence: 99%

Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem

Koo¹,

Auletta²,

Hartley³

et al. 2022

Transplantation and Cellular Therapy

View full text Add to dashboard Cite

Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal

Cited by 18 publications

References 18 publications

Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 pandemic: a single center experience

Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 pandemic: a single center experience

Impact of Covid 19 pandemic on hematopoietic stem cell transplantation activities: Report from a single center

Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem

Contact Info

Product

Resources

About